Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

Suggested remit: To appraise the clinical and cost effectiveness of obecabtagene autoleucel within its marketing authorisation for treating relapsed or refractory B-cell acute lymphoblastic leukaemia.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6347

Provisional Schedule

Committee meeting:

21 August 2025

Expected publication:

15 October 2025

Project Team

Project lead

Leena Issa

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors

Autolus

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Anthony Nolan

 

Leukaemia Care

 

Leukaemia UK

Professional groups

Association of Cancer Physicians

 

Cancer Research UK

 

Royal College of Physicians

 

Royal College of Radiologists

Associated public health groups

None

Comparator companies

AAH Pharmaceuticals (dasatinib, imatinib) (confidentiality agreement not signed, not participating)

 

Accord UK (cytarabine, filgrastim, fludarabine, imatinib, pegfilgrastim) (confidentiality agreement not signed, not participating)

 

Amarox (imatinib) (confidentiality agreement not signed, not participating)

 

Amgen (blinatumomab, filgrastim, pegfilgrastim) (confidentiality agreement not signed, not participating)

 

Aurobindo (Milpharm) (imatinib) (confidentiality agreement not signed, not participating)

 

Chugai Pharma UK Ltd (lenograstim) (confidentiality agreement not signed, not participating)

 

Cipla EU (imatinib) (confidentiality agreement not signed, not participating)

 

Dr. Reddy’s Laboratories (imatinib) (confidentiality agreement not signed, not participating)

 

Hospira UK (cytarabine) (confidentiality agreement not signed, not participating)

 

Incyte Biosciences UK (ponatinib) (confidentiality agreement not signed, not participating)

 

Mylan (dasatinib) (confidentiality agreement not signed, not participating)

 

Napp Pharmaceuticals (pegfilgrastim) (confidentiality agreement not signed, not participating)

 

Novartis (imatinib, tisagenlecleucel) (confidentiality agreement signed, participating)

 

Pfizer (cytarabine, filgrastim, idarubicin, inotuzumab ozogamicin) (confidentiality agreement not signed, not participating)

 

Sandoz (dasatinib, filgrastim, imatinib, pegfilgrastim) (confidentiality agreement not signed, not participating)

 

Sanofi (fludarabine) (confidentiality agreement not signed, not participating)

 

Teva UK (dasatinib, fludarabine, lipegfilgrastim) (confidentiality agreement not signed, not participating)

 

Viatris UK Healthcare (dasatinib)(confidentiality agreement not signed, not participating)

 

Zentiva (dasatinib) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health – Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

Institute of Cancer Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual